PTGX Protagonist Therapeutics Earnings and EPS analysis

Relative Growth: Rel. Growth: 91

Relative Strength: Rel. Strength: 91

Relative Valuation: Rel. Valuation: 12

Relative Profitability: Rel. Profitability: 95

EPS in 2026 (TTM): $1.21

Last Report Period Date: Jun 30, 2026

According to the most recent financial data from June 2026, the current EPS (TTM) is $1.21. Protagonist Therapeutics's EPS for 2025 came in at -$2.05, marking a decrease from $4.47 in 2024. For the quarterly period ending on Jun 30, 2026, PTGX's EPS was $2.47.

PTGX earnings history

Historical annual and quarterly earnings per share (EPS) data for Protagonist Therapeutics

EPS (TTM)

$1.21

EPS Growth YoY (Quarterly)

549.1%

EPS (Quarterly)

$2.47

EPS Growth (Quarterly)

4,016.7%

Protagonist Therapeutics had an annual EPS of -$2.05, marking a decrease of 145.9% from $4.47 in 2024. The quarterly EPS for the period ending Jun 30, 2026, was $2.47, marking a 549.1% increase from the same quarter last year. PTGX's TTM EPS stands at $1.21 as of June 2026. Protagonist Therapeutics's EPS for 2024 stood at $4.47, a 421.6% increase from 2023.

PTGX EPS vs price chart

PTGX EPS growth history

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

549.1%

EPS growth YoY

-145.9%

EPS growth 3Y avg

N/A

EPS growth 5Y avg

N/A

Protagonist Therapeutics has recorded an increase in EPS of 549.1% over the last 12 months (YoY, quarterly).

PTGX Earnings Waterfall

Breakdown of revenue, profit and net income for Protagonist Therapeutics

PTGX Earnings vs Peers

What are the earnings of PTGX compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
ORMP Oramed Pharmaceuticals Inc	1.12	418.8%	N/A	N/A
OMER Omeros Corp	10.86	98.1%	N/A	N/A
PTGX Protagonist Therapeutics Inc	114.63	-145.9%	N/A	N/A
OLMA Olema Pharmaceuticals Inc	N/A	15%	N/A	N/A
VIVS VivoSim Labs Inc.	N/A	-214.7%	N/A	N/A
ORIC Oric Pharmaceuticals Inc	N/A	19.7%	N/A	N/A

All data is based on quarterly TTM periods, unless otherwise specified.